Finch Therapeutics Group
Stock Forecast, Prediction & Price Target
Finch Therapeutics Group Financial Estimates
Finch Therapeutics Group Revenue Estimates
Finch Therapeutics Group EBITDA Estimates
Finch Therapeutics Group Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $18.53M N/A | $861K -95.35% | $107K -87.57% | Avg: $88.5M Low: $88.5M High: $88.5M avg. 82610.28% | Avg: $345.4M Low: $345.4M High: $345.4M avg. 290.28% | ||
Net Income
% change YoY
| $-55.85M N/A | $-113.69M -103.54% | $-74.75M 34.25% | Avg: $-17.32M Low: $-17.32M High: $-17.32M avg. 76.81% | Avg: $85.68M Low: $85.68M High: $85.68M avg. 594.44% | ||
EBITDA
% change YoY
| $-59.98M N/A | $-74.64M -24.44% | $-32.48M 56.48% | Avg: $-88.5M Low: $-88.5M High: $-88.5M avg. -172.45% | Avg: $-345.4M Low: $-345.4M High: $-345.4M avg. -290.28% | ||
EPS
% change YoY
| -$35.27 N/A | -$71.52 -102.77% | -$46.59 34.85% | Avg: -$10.8 Low: -$10.8 High: -$10.8 avg. 76.81% | Avg: $53.4 Low: $53.4 High: $53.4 avg. 594.44% | ||
Operating Expenses
% change YoY
| $78.51M N/A | $95.98M 22.24% | $32.58M -66.04% | Avg: $5.29B Low: $5.29B High: $5.29B avg. 16162.66% | Avg: $20.68B Low: $20.68B High: $20.68B avg. 290.28% | ||
FAQ
What is Finch Therapeutics Group stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 335.63% in 2025-2026.
We have gathered data from N/A analysts. Their low estimate is -17.32M, average is -17.32M and high is -17.32M.
What is Finch Therapeutics Group stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 41450.28% in 2025-2026.
We have gathered data from N/A analysts. Their low revenue estimate is $88.5M, average is $88.5M and high is $88.5M.
What is Finch Therapeutics Group stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 335.63% in 2025-2026.
We have gathered data from N/A analysts. Their low earnings per share estimate is -$10.8, average is -$10.8 and high is $-10.8.
What is the best performing analyst?
In the last twelve months analysts have been covering Finch Therapeutics Group stock. The most successful analyst is Roger Song.